Skip to content

BIIB · BIOGEN INC.

30 filings

10-K

BIIB 10-K Annual Reports

BIOGEN INC. - 30 annual reports

Filing record · 2016–202610-K1110-Q328-K112

2025
BIOGEN INC. Annual Report, Year Ended Dec 31, 2025
Biogen's FY2025 10-K shows a company in transition: total revenue grew 2.2% to $9.89 billion, but product revenue fell 1.3% to $7.12 billion as MS franchise erosion (down 7.1%, driven by TECFIDERA generics and TYSABRI biosimilar competition) offset growth in rare disease (up 8.4%) and new launches. Diluted EPS fell 21.4% to $8.79, reflecting higher acquired IPR&D and upfront/milestone expense ($471.8 million, up from $61.5 million), a $104.9 million royalty cost charge tied to a litigation matter, $139.5 million of other litigation-related expense (including the Convergence settlement in principle), and a $52.9 million ROU asset impairment on the Reata Plano lease. Cash generation weakened: operating cash flow fell to $2.2 billion from $2.9 billion, partly due to roughly $864 million of tax payments. Cash, equivalents and marketable securities rose to $4.2 billion, helped by $200 million of Royalty Pharma litigation-related funding for litifilimab and $1.75 billion of new senior notes that refinanced the 2025 maturity. Total borrowings were essentially flat at $6.3 billion, and the $2.1 billion remaining buyback authorization went unused in 2025. Looking ahead, management expects continued MS revenue decline, growth in rare disease (SKYCLARYS, QALSODY), flat SPINRAZA, and a slight increase in core R&D in 2026, with relatively flat SG&A. Key catalysts include the April 3, 2026 PDUFA for high-dose SPINRAZA, the May 24, 2026 PDUFA for LEQEMBI IQLIK starting dose, late-stage readouts for felzartamab, litifilimab and zorevunersen, and the 2026 Phase 3 start for salanersen. Risks include pricing pressure from the IRA and MFN policy, ongoing litigation (including a $124.3 million Genentech judgment under appeal and a German tax assessment of about $246.5 million), and dependence on the Eisai LEQEMBI collaboration.
Feb 6, 2026
2024
BIOGEN INC. Annual Report, Year Ended Dec 31, 2024
Biogen's FY2024 Form 10-K (filed February 12, 2025) shows a company in transition: total revenue fell 1.6% to $9.68 billion, while diluted EPS rose 40.3% to $11.18, helped by lower R&D and SG&A spending under the Fit for Growth cost program and by a $1.6 billion increase in amortization and impairment charges that was more than offset elsewhere. Product revenue was essentially flat at $7.21 billion, with MS revenue down 6.7% to $4.35 billion because of TECFIDERA generic erosion, TYSABRI competition and lower interferon demand. Rare disease grew 10.3% to $1.99 billion, led by the first full year of SKYCLARYS ($382.5 million) and ZURZUVAE, though this was partly offset by lower SPINRAZA sales outside the U.S. The balance sheet and cash flow improved. Operating cash flow rose 86% to $2.88 billion, cash and equivalents reached $2.38 billion, and the company repaid $650 million of its 2023 term loan. Total borrowings fell to $6.30 billion, but $1.75 billion of 4.05% Senior Notes mature in September 2025, which pushed current liabilities up sharply and reduced working capital to $1.93 billion. The company completed the $1.15 billion HI-Bio acquisition, which added the felzartamab pipeline and roughly $650 million of potential milestones, and sold its rare pediatric priority review voucher for $88.6 million net. No share repurchases were made in 2024, leaving about $2.1 billion authorized. The main investor concerns are the continued decline of the MS franchise, biosimilar and generic pressure on RITUXAN, TECFIDERA and TYSABRI, IRA-related revenue headwinds estimated at $50-100 million for 2025, and the LEQEMBI launch, which still depends on EU and Australia regulatory outcomes. Management expects MS revenue to keep declining in 2025 while rare disease grows. Core R&D is expected to fall, but the company is still funding pipeline investments and facing a 2025 debt maturity wall.
Feb 12, 2025
2023
BIOGEN INC. Annual Report, Year Ended Dec 31, 2023
Biogen's FY2023 10-K shows a company in transition: total revenue fell 3.3% to $9.84 billion and diluted EPS dropped 61.8% to $7.97, as multiple sclerosis franchise erosion (MS product revenue down 14.1%, driven by TECFIDERA generics) outpaced growth elsewhere. Net income attributable to Biogen was $1.16 billion versus $3.05 billion in 2022, which included a $1.5 billion gain on the Samsung Bioepis sale and a $900 million litigation charge. Results were also affected by roughly $393 million of one-time equity compensation tied to the September 2023 Reata acquisition, $212.5 million of Fit for Growth restructuring charges, and $1.3 billion of SKYCLARYS inventory step-up adjustments flowing through inventory. The balance sheet and capital allocation changed materially. Biogen spent roughly $6.9 billion on the Reata acquisition, funded largely from cash and a $1.0 billion term loan. Cash and marketable securities fell from $5.6 billion to $1.0 billion, total borrowings rose to $6.9 billion, and no share repurchases were made in 2023, leaving about $2.1 billion under the authorization. Operating cash flow was $1.55 billion. Management expects MS revenue to keep declining in 2024, with growth driven by LEQEMBI, SKYCLARYS and the Fit for Growth program, which targets $800 million in net operating expense savings by 2025. Key risks include continued generic and biosimilar competition, uncertain LEQEMBI launch economics and reimbursement, IRA drug pricing pressure, an underutilized Solothurn manufacturing plant generating excess-capacity charges, and ongoing litigation including ADUHELM securities actions, a Genentech royalty claim of about $88 million, and government investigations. The company also announced it is exploring strategic options for its biosimilars business.
Feb 14, 2024
2022
BIOGEN INC. Annual Report, Year Ended Dec 31, 2022
Biogen's FY2022 10-K (filed February 15, 2023) shows a company in transition: total revenue fell 7.4% to $10.17 billion, with product revenue down 9.7% to $7.99 billion, driven mainly by generic TECFIDERA erosion (down 26%) and biosimilar competition to RITUXAN. Diluted EPS nearly doubled to $20.87, but that was inflated by one-time items, including a roughly $1.5 billion pre-tax gain on the sale of the 49.9% Samsung Bioepis stake and a $503.7 million gain on the 125 Broadway building sale, partly offset by a $917 million litigation settlement charge and $275 million of ADUHELM inventory write-offs after the CMS coverage decision. Underlying operations are under pressure as legacy MS franchises decline. Management expects TECFIDERA and interferon revenue to keep falling in 2023 and guides to flat SPINRAZA and TYSABRI and modest biosimilar growth. The company has $5.6 billion in cash and marketable securities against $6.3 billion of long-term notes, and ended the year with $2.1 billion remaining on its buyback authorization after repurchasing roughly $750 million of stock in 2022. Operating cash flow fell 62% to $1.38 billion, partly due to the litigation payment and higher tax payments. The main investor debates are the pace of the company's pivot to neurology and neuropsychiatry, centered on the January 2023 accelerated approval of LEQEMBI (co-developed with Eisai) and the zuranolone PDUFA date of August 5, 2023, and whether cost-reduction savings of about $1.0 billion and the planned exploration of strategic options for the biosimilars business can offset revenue erosion. Its ADUHELM setback and the House committee investigation remain overhangs.
Feb 15, 2023
2021
BIOGEN INC. Annual Report, Year Ended Dec 31, 2021
Biogen's FY2021 10-K shows a sharp earnings reset driven by the erosion of its TECFIDERA franchise. Total revenue fell 18.3% to $10,981.7 million from $13,444.6 million, and product revenue, net declined 17.3% to $8,846.9 million, led by a 22.2% drop in MS product revenue as multiple U.S. TECFIDERA generics launched. Diluted EPS fell 58.1% to $10.40 from $24.80. Operating income declined to $2,840.7 million from $4,550.1 million, and net other expense of $1,095.5 million, which includes $824.9 million of investment losses on equity stakes in Denali, Sage, Sangamo and Ionis, further compressed results. Total cost and expense fell 8.5% to $8,141.0 million, but this was largely due to 2020's $1.9 billion in collaboration upfront payments, and cost of sales rose 16.9% on a $164.0 million ADUHELM inventory charge. The balance sheet and cash generation remain solid. Operating cash flow was $3,639.9 million, cash and marketable securities totaled $4,694.5 million, and the company repurchased $1.8 billion of stock during 2021. Management expects TECFIDERA revenue to keep declining in 2022, SPINRAZA to face more competition, and only minimal ADUHELM sales, which is a notable concern given the product's accelerated approval and the uncertain final Medicare coverage decision (NCD). Strategically, Biogen is pivoting toward neuroscience and specialized immunology through licensing and collaboration deals (InnoCare, BIIB115, mosunetuzumab) and by selling its Samsung Bioepis stake for $1.0 billion at closing plus $1.3 billion in deferred payments, with closing expected in mid-2022. Pipeline setbacks included the BIIB067 (tofersen) Phase 3 failure and the discontinuation of several gene therapy and tau programs, with $629.3 million in impairments.
Feb 3, 2022
2020
BIOGEN INC. Annual Report, Year Ended Dec 31, 2020
Biogen's FY2020 10-K (filed February 3, 2021) shows a year of heavy investment and pipeline expansion that compressed reported earnings. Total revenues fell 6.5% to $13.44 billion, driven by an 8.2% decline in MS product revenues and a 31.7% drop in U.S. RITUXAN revenues as biosimilars entered the market. TECFIDERA faced multiple U.S. generic entrants, which significantly reduced its revenues and is expected to keep weighing on results. Diluted EPS fell 21.1% to $24.80, net income attributable to Biogen was $4.0 billion, and operating cash flow was $4.23 billion, down from $7.08 billion in 2019. R&D expense rose 75% to $3.99 billion, largely due to roughly $1.9 billion in upfront payments and collaboration equity premiums tied to new deals with Sangamo, Denali and Sage. The company also deployed significant capital to shareholders, repurchasing about $6.7 billion of stock in 2020 and issuing $3.0 billion of senior notes, which pushed total borrowings to $7.4 billion. Cash and marketable securities declined to $3.4 billion from $5.9 billion. A $5.0 billion repurchase program was authorized in October 2020. The near-term outlook is dominated by aducanumab for Alzheimer's disease, where the PDUFA date was extended to June 7, 2021 after a majority of the FDA advisory committee voted against efficacy. Management expects SG&A to rise significantly in 2021 to support a potential launch, and expects declining TECFIDERA and interferon sales. Investors should weigh the upside of a potential Alzheimer's launch and the pipeline against near-term revenue pressure, a large valuation allowance on deferred tax assets, and the ongoing litigation, including a new securities class action tied to aducanumab.
Feb 3, 2021
2019
BIOGEN INC. Annual Report, Year Ended Dec 31, 2019
Biogen closed 2019 with record profitability: total revenues rose 6.9% to $14.38 billion, and diluted EPS jumped 45.6% to $31.42, aided by a lower effective tax rate of 16.3% (versus 24.2% in 2018), a $205 million tax benefit from an IP reorganization and Swiss tax reform, and a $204.7 million investment gain. Net income reached $5.89 billion. Growth was led by SPINRAZA (up 21.6% to $2.10 billion), biosimilars (up 35.4%), and OCREVUS royalties (anti-CD20 revenues up 15.7%). TECFIDERA grew 3.7% and remains the largest product, though the U.S. MS franchise is under pressure from OCREVUS and interferon declines. Operating cash flow was $7.08 billion, and the company returned about $5.9 billion through share repurchases while holding $5.9 billion in cash and marketable securities against $5.95 billion of borrowings. The filing highlights several forward-looking risks. TECFIDERA faces potential generic entry before its '514 patent expires in February 2028, following settlements and pending litigation, and a PTAB decision upheld the patent in February 2020 (appealable). Competition is intensifying in MS, SMA (including a new gene therapy approved in May 2019), and oncology, where RITUXAN biosimilars launched in November 2019 and January 2020. Management also flagged significant spending ahead: SG&A is expected to rise sharply in 2020 to support the potential aducanumab launch, and the company expects approximately $430 million in milestone payments in 2020, including $75 million on aducanumab's FDA filing. Biogen is also building a large Solothurn, Switzerland biologics facility, expected to be partially operational by end-2020, with $2.0 billion of long-lived assets tied to it. Pipeline and portfolio activity was active: the Nightstar acquisition added ophthalmology assets, the Hillerød manufacturing site was sold to FUJIFILM, Biogen acquired ophthalmology biosimilar rights from Samsung Bioepis, and it exercised its option on BIIB080 (tau ASO). Biogen also announced plans to pursue FDA approval for aducanumab in AD after the EMERGE study met its primary endpoint, despite the earlier futility-based discontinuation of the Phase 3 trials. Several pipeline programs failed or were discontinued in 2019, including BG00011 (IPF, $215.9 million impairment), gosuranemab in PSP, and elenbecestat.
Feb 6, 2020
2018
BIOGEN INC. Annual Report, Year Ended Dec 31, 2018
Biogen's FY2018 10-K shows a year of strong top-line and earnings growth, driven by SPINRAZA launch momentum, biosimilar growth, and rising anti-CD20 program revenues, offset by a heavy R&D investment load and continued MS franchise erosion. Total revenues rose 9.6% to $13.45 billion, product revenues rose 5.1% to $10.89 billion, and revenues from anti-CD20 programs rose 27.0% to $1.98 billion. Diluted EPS was $21.58, up 81% from $11.92 in 2017, although the comparison is distorted by the $1.17 billion Transition Toll Tax provision booked in 2017; the 2018 effective tax rate fell to 24.2% from 47.9%. Beneath the headline numbers, the MS franchise is under pressure: MS product revenues fell 4.3%, with Interferon (AVONEX/PLEGRIDY) down 10.7% and TYSABRI U.S. volumes down 9%. Management expects continued declines in Interferon and TYSABRI demand in 2019, citing competition from OCREVUS and other MS therapies. SPINRAZA ($1.72 billion, up 95%) and biosimilars ($545 million, up 44%) are the main growth engines, though management expects SPINRAZA growth to moderate in 2019. Operating cash flow was strong at $6.19 billion, supporting $4.4 billion in share repurchases, but cash and marketable securities fell to $4.9 billion from $6.7 billion. Notable pipeline risks include the Phase 2 ACTION failure, the vixotrigine impairments, and the Phase 2b dapirolizumab miss, and a potential 2019 U.S. biosimilar entry for RITUXAN. The 2018 results also include significant one-time charges, most notably the $486 million R&D charge from the Ionis collaboration, which is captured in reported results and should be considered when assessing underlying profitability.
Feb 6, 2019
2017
BIOGEN INC. Annual Report, Year Ended Dec 31, 2017
Biogen's 2017 10-K shows a company whose core earnings remained strong but whose reported profitability was sharply reduced by one-time items. Total revenues rose 7.2% to $12.27 billion, led by product revenues of $10.35 billion (up 5.5%), with SPINRAZA ($884 million), TECFIDERA ($4.21 billion) and BENEPALI ($371 million) driving growth, partially offset by the February 2017 spin-off of the hemophilia business (Bioverativ), declining Interferon sales, and the loss of hemophilia revenues. Anti-CD20 program revenues grew 18.6% to $1.56 billion on OCREVUS royalties and higher RITUXAN profit share. Net income attributable to Biogen fell to $2.54 billion from $3.70 billion, and diluted EPS fell 29.6% to $11.92. The decline was driven primarily by a $1.17 billion charge for the 2017 Tax Act (including a $989.6 million Transition Toll Tax payable over eight years), $444.2 million of Forward Pharma TECFIDERA-license amortization and impairment, a $120 million acquired IPR&D charge for BIIB093, and a rise in R&D to $2.25 billion (up 14.2%) that included several large upfront and milestone payments to collaborators. Cash flow from operations held steady at $4.55 billion, but cash, equivalents and marketable securities declined to $6.75 billion, and the company repurchased about $1.4 billion of stock. Investors should weigh the company's concentration risk: MS products remain the core of revenue, with OCREVUS (approved 2017) and MS competition expected to pressure TECFIDERA and TYSABRI volumes in the U.S. in 2018. The ZINBRYTA EU restrictions led to roughly $191 million in net impairment charges, and a $2.0 billion+ pipeline of late-stage programs (aducanumab, BIIB098, SPINRAZA expansion) represents both the growth thesis and substantial remaining development and milestone obligations of roughly $4.2 billion.
Feb 1, 2018
2016
BIOGEN INC. Annual Report, Year Ended Dec 31, 2016
Biogen's 2016 Form 10-K shows a strong year financially: total revenues rose 6.4% to $11.45 billion, diluted EPS grew 10.4% to $16.93, and net income attributable to Biogen was $3.70 billion. Product revenues reached $9.82 billion, led by TECFIDERA (+9.1% to $3.97 billion). Results were partly offset by a $454.8 million pre-tax charge tied to the January 2017 $1.25 billion settlement and license agreement with Forward Pharma, a $454.8 million TECFIDERA litigation charge, and rising interest expense following the 2015 $6.0 billion senior notes issuance. Operating cash flow was $4.5 billion, and cash, equivalents and marketable securities totaled $7.7 billion against roughly $6.5 billion of debt. The filing is dominated by portfolio transition. Biogen completed the spin-off of its hemophilia business, Bioverativ (BIVV), on February 1, 2017, with shareholders receiving one Bioverativ share for every two Biogen shares. Going forward, Biogen's revenue will be more concentrated in MS (TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, ZINBRYTA) and SPINRAZA, which launched in the U.S. in December 2016. Management also ceased manufacturing at its Cambridge, MA facility, a move that added accelerated depreciation and restructuring costs in 2016. Key pipeline items include aducanumab for Alzheimer's disease, now in Phase 3 with Fast Track designation, and several neurology and autoimmune programs. Investors should weigh the MS franchise's competitive exposure, including the anticipated erosion of AVONEX and rising competition from OCREVUS and oral therapies, against the company's cash generation and capital return program, which included $1.0 billion of share repurchases in 2016 under a $5.0 billion authorization. Pricing pressure in the U.S. and Europe, the Forward Pharma and Italian AIFA matters, and the success of the late-stage pipeline remain the main risks.
Feb 2, 2017
2015
BIOGEN INC. Annual Report, Year Ended Dec 31, 2015
Biogen's fiscal 2015 10-K shows a company at a major inflection point. Total revenues rose 10.9% to $10,763.8 million and diluted EPS increased 24.0% to $15.34, driven by TECFIDERA (up 25.1% to $3,638.4 million), new hemophilia launches (ELOCTATE and ALPROLIX, together about $554 million), and a 12.0% rise in the company's share of RITUXAN and GAZYVA U.S. profits. Income from operations reached $4,891.0 million. Partially offsetting this, AVONEX fell with unit volume down 17% in the U.S., TYSABRI revenue declined, and foreign currency losses of about $388 million reduced product revenue. Cash flow from operations was $3,716.1 million, and cash, equivalents and marketable securities reached $6,188.9 million after the $6.0 billion senior notes issuance. Capital allocation was aggressive in 2015. Biogen repurchased and retired about 16.8 million shares for $5.0 billion under its share repurchase program, funded partly by the $6.0 billion September 2015 debt offering. Total borrowings rose from $583.4 million to $6,526.3 million, and shareholders' equity fell to $9,372.8 million from $10,809.0 million. The company also paid $850.0 million in Fumapharm contingent payments and acquired Convergence Pharmaceuticals, while a restructuring (October 2015) with an 11% workforce reduction and pipeline terminations is expected to cut annual operating costs by about $250 million. The key risks for investors are concentration and pipeline setbacks. TECFIDERA is increasingly important, the MS market is crowded, and TYSABRI's SPMS Phase 3 study (ASCEND) failed in October 2015, causing that development to be discontinued. Patent challenges to TECFIDERA (Forward Pharma litigation and inter partes review) and a securities class action are pending, and several government investigations into sales practices are ongoing. The company's growth now depends on aducanumab for Alzheimer's disease (Phase 3 ENGAGE and EMERGE underway), nusinersen for SMA, ocrelizumab royalties via Genentech, and biosimilars through Samsung Bioepis.
Feb 3, 2016
2014
BIOGEN INC. Annual Report, Year Ended Dec 31, 2014
Biogen Idec's FY2014 10-K shows a company in a strong commercial inflection, with total revenues rising 40.0% to $9.70 billion and income from operations up 57.9% to $3.97 billion. Diluted EPS reached $12.37 versus $7.81 in 2013. Growth was driven primarily by TECFIDERA, which generated $2.91 billion in worldwide revenue (up 232%), alongside TYSABRI ($1.96 billion, up 28%) and the launch of PLEGRIDY, ALPROLIX and ELOCTATE. AVONEX remained flat at $3.01 billion, and unconsolidated RITUXAN/GAZYVA joint business revenue grew 6.2% to $1.20 billion. The filing also flags meaningful headwinds and dependencies. Management expects roughly $130 million lower royalty revenue in 2015 as ANGIOMAX royalties ended with patent expiry in December 2014, and amortization of acquired intangibles is projected to decline modestly from $344 million in 2015. Revenue remains concentrated in MS products, with TECFIDERA, AVONEX, TYSABRI and RITUXAN named as principal products, and competition, pricing pressure in Europe and the U.S., and generic/biosimilar entry are cited as key risks. Two wholesalers (AmerisourceBergen and McKesson) account for a large share of gross product revenue, and receivables in Spain, Italy and Portugal remain slow to collect. Cash, cash equivalents and marketable securities rose to $3.32 billion, operating cash flow was $2.94 billion, and the company repurchased $887 million of stock during the year. Pipeline commitments are substantial, with about $2.8 billion in potential milestone payments to third parties and a Fumapharm contingent payment obligation that continues to grow with TECFIDERA sales. The company also announced a planned $200 million upfront acquisition of Convergence Pharmaceuticals in January 2015.
Feb 4, 2015
2013
BIOGEN INC. Annual Report, Year Ended Dec 31, 2013
Biogen Idec (BIIB) closed 2013 with a sharply stronger top line and earnings, driven primarily by the April 2013 acquisition of full ownership of TYSABRI from Elan for a $3.25 billion upfront payment. Total revenues rose 25.7% to $6,932.2 million, net income attributable to Biogen Idec rose 34.9% to $1,862.3 million, and diluted EPS reached $7.81 versus $5.76 in 2012. Product revenues grew 33.0% to $5,542.3 million, with U.S. TYSABRI now recognized at 100% and TECFIDERA contributing $876.1 million in its first year on the market. Note that Biogen's reported figures include a one-time items: a $38.5 million net tax benefit and a $49.8 million uncertain-tax-position benefit, offset by the $75.0 million Isis upfront charge and a $27.2 million Weston facility exit charge. The growth picture is more mixed beneath the headline. AVONEX grew only 3.2% to $3,005.5 million, with U.S. unit volume down 8% as patients transitioned to TECFIDERA, and rest-of-world pricing pressured by European austerity measures. Cost and expense growth outpaced revenue in several lines: total cost and expenses rose 19.8%, SG&A rose 34.0% on TECFIDERA and hemophilia launch preparation, and amortization of acquired intangibles jumped 69.6% to $342.9 million, with schedules implying $426.3 million in 2014. Cash, cash equivalents and marketable securities fell to $1,848.5 million from $3,742.4 million after the TYSABRI purchase, the repayment of $450 million of 6.0% Senior Notes, and $400.3 million in share repurchases, although operating cash flow was a strong $2,345.1 million. Looking ahead, the key investor questions concern TECFIDERA's commercial trajectory in the U.S. and E.U. (with about $134.0 million of U.S. revenue still in channel inventory at year-end), the pending FDA decisions on ELOCTATE and ALPROLIX after three-month PDUFA extensions, the PLEGRIDY regulatory reviews, and the expected drop in ANGIOMAX royalties when its U.S. patent expires on December 15, 2014. Exposure to European receivables in Spain, Italy and Portugal, the TYSABRI PML label risk, and an estimated $900 million to $1 billion residual U.S. tax on repatriation are additional considerations.
Feb 6, 2014
2012
BIOGEN INC. Annual Report, Year Ended Dec 31, 2012
Biogen Idec (BIIB) closed fiscal 2012 with record results driven by its three core products: AVONEX, TYSABRI and RITUXAN. Total revenues rose 9.3% to $5,516.5 million, income from operations increased 7.6% to $1,855.8 million, and diluted EPS grew 14.3% to $5.76 (net income attributable to Biogen Idec of $1,380.0 million). Growth was led by AVONEX ($2,913.1 million, up 8.4%), TYSABRI ($1,135.9 million, up 5.2%) and RITUXAN unconsolidated joint business revenue ($1,137.9 million, up 14.2%). Total cost and expenses rose 11.5%, largely from higher SG&A (up 21%) and R&D (up 9.5%) as the company prepares for launches of TECFIDERA, long-lasting Factor VIII and Factor IX, and continues investing in FAMPYRA commercialization. The company's pipeline and regulatory outlook is central to the investment case. TECFIDERA's FDA PDUFA date was extended to late March 2013 and it has an EMA application under review; the U.S. launch is expected in Q2 2013. Factor IX has a BLA under review and Factor VIII is expected to be filed in 1H 2013. Peginterferon beta-1a met its Phase 3 ADVANCE endpoints, with filings planned by mid-2013. Setbacks included the failure of dexpramipexole in ALS, which was discontinued at year-end 2012. Biogen also faces ongoing risks: heavy dependence on three products, PML-related label pressure on TYSABRI, European austerity and slow collections in Italy, Spain and Portugal, a pending Hoechst arbitration affecting RITUXAN, and an IRS proposed disallowance of about $130 million. Capital allocation remained shareholder-friendly, with $984.7 million in share repurchases in 2012 and about $1.9 billion in operating cash flow. Cash, equivalents and marketable securities reached $3.74 billion, against $1.14 billion in borrowings, including $450 million of 6.0% senior notes due March 2013 that will need to be refinanced or repaid. Management expects revenue headwinds from European pricing measures of roughly $45–60 million in 2013.
Feb 5, 2013
2011
BIOGEN INC. Annual Report, Year Ended Dec 31, 2011
Biogen Idec reported total revenues of $5.05 billion for the year ended December 31, 2011, representing a 7.0% increase compared to the previous year. This growth was primarily driven by strong performance in AVONEX and TYSABRI, which saw revenue increases of 6.7% and 19.9% respectively. TYSABRI's strong growth, in particular, highlights its increasing importance to the company's financial health, despite ongoing concerns regarding its safety profile and the associated risk management programs. The company also saw a 22.8% increase in net income attributable to Biogen Idec Inc., reaching $1.23 billion, or $5.04 per diluted share. Looking ahead, Biogen Idec's long-term success hinges on the continued sales of its key products and the successful development and commercialization of its pipeline candidates, notably BG-12 for multiple sclerosis. The company's investment in research and development remains substantial, underscoring its commitment to innovation. However, investors should remain mindful of the competitive landscape, potential regulatory hurdles, and the company's dependence on a few core products, as highlighted in the risk factors.
Feb 3, 2012
2010
BIOGEN INC. Annual Report, Year Ended Dec 31, 2010
Biogen Idec's 2010 10-K report highlights a company focused on neurological disorders with a portfolio driven by AVONEX, TYSABRI, and RITUXAN. Total revenues grew by 7.7% to $4.7 billion, primarily fueled by strong performance in AVONEX and TYSABRI, which saw revenue increases of 8.4% and 16.0% respectively. Despite an overall increase in revenue, income from operations saw a slight decrease of 3.6% due to increased restructuring charges, a significant acquired in-process R&D charge, and higher collaboration profit sharing expenses. The company is undergoing a significant strategic shift, announced in late 2010, to focus primarily on neurology and reallocate R&D resources. This includes terminating or out-licensing oncology and cardiovascular programs and reducing workforce by 13%. Several business development activities occurred in 2010, including the acquisition of Panima Pharmaceuticals AG and new collaboration terms for ocrelizumab and GA101 with Genentech, alongside a license agreement for dexpramipexole. Investors should note the ongoing safety monitoring and regulatory discussions for TYSABRI related to PML risks. Looking ahead, Biogen Idec expects continued competition in the Multiple Sclerosis market and is actively managing its product pipeline and operational structure to drive future growth. The company's financial position remains robust with significant cash reserves, and it actively repurchased shares in 2010.
Feb 4, 2011
2009
BIOGEN INC. Annual Report, Year Ended Dec 31, 2009
Biogen Idec Inc. (BIIB) reported robust revenue growth in 2009, primarily driven by strong performance from its key products AVONEX and TYSABRI, alongside contributions from RITUXAN. Total revenues reached $4.38 billion, with net income attributable to Biogen Idec Inc. increasing by a significant 23.9% to $970.1 million. The company demonstrated substantial investment in research and development, with R&D expenses rising by nearly 20% to $1.28 billion, reflecting its commitment to pipeline advancement in neurology, oncology, and immunology. Financially, Biogen Idec maintained a strong liquidity position with approximately $2.46 billion in cash, cash equivalents, and marketable securities. The company also actively returned capital to shareholders through share repurchases, totaling $751.2 million in 2009 under its repurchase programs. Management highlighted continued growth expectations for TYSABRI and AVONEX, while also navigating competitive pressures and regulatory developments in the biotechnology sector. The company announced a CEO transition, with the current CEO set to retire in June 2010, and initiated a search for a successor.
Feb 9, 2010
2008
BIOGEN INC. Annual Report, Year Ended Dec 31, 2008
Biogen Idec Inc. (BIIB) reported strong financial performance for the year ended December 31, 2008, with total revenues reaching $4.1 billion. The company's primary revenue drivers, AVONEX (for multiple sclerosis) and RITUXAN (for lymphoma and rheumatoid arthritis), continued to show robust sales growth, contributing approximately 81% of total revenues. TYSABRI, a newer product for multiple sclerosis and Crohn's disease, demonstrated significant revenue growth, indicating increasing market acceptance despite ongoing safety monitoring. The company significantly increased its investment in research and development, spending over $1 billion to advance its pipeline, with 22 products in Phase 2 trials or beyond. This strategic investment highlights Biogen Idec's commitment to future growth through innovation in neurology, oncology, and immunology. Despite the company's strong financial position and product portfolio, it faces increasing competition and the potential impact of biosimilars on its key products. The report also details ongoing collaborations and potential future product development, providing a comprehensive view of the company's operational and strategic landscape.
Feb 6, 2009
2007-A
BIOGEN INC. Annual Report (Amendment), Year Ended Dec 31, 2007
This 10-K filing for Biogen Inc. (BIIB) as of April 29, 2008, primarily details the company's corporate governance, executive compensation, and security ownership. The report emphasizes the 'pay-for-performance' philosophy guiding executive compensation, with a focus on aligning executive incentives with company financial, strategic, and operational goals. Compensation is benchmarked against a peer group of biotechnology and pharmaceutical companies, with base salaries targeted at the median, and long-term incentives set between the median and 75th percentile. Key disclosures include the composition of the Board of Directors and its committees, highlighting the independence of most directors. The report details the compensation structure for named executive officers, including base salary, annual cash incentives, and long-term incentives (stock options and restricted stock units). It also outlines severance benefits for executives under various termination scenarios, including those related to corporate transactions or change in control. For investors, understanding the link between executive pay and company performance, as well as the terms of severance packages, is crucial for assessing management alignment and potential shareholder value.
Apr 29, 2008
2007
BIOGEN INC. Annual Report, Year Ended Dec 31, 2007
Biogen Idec's 2007 10-K shows a year of strong top-line growth and a transformative, debt-funded capital return. Total revenues rose 18% to $3,171.6 million and net income climbed to $638.2 million, or $1.99 diluted EPS, versus $217.5 million ($0.63) in 2006 (which included a $330.5 million IPR&D charge). Growth was driven by AVONEX ($1,867.8 million, up 9%), TYSABRI's relaunch ($229.9 million, up from $35.8 million), and RITUXAN copromotion and royalty income from Genentech ($926.1 million, up 14%). Operating margins improved, though R&D rose 29% to $925.2 million to fund a broad late-stage pipeline. The defining event of the year was a July 2007 Dutch Auction tender offer that repurchased 56.4 million shares at $53.00 for $2,990.5 million. It was funded with $1,490.5 million of cash and a $1,500.0 million 364-day term loan due June 2008. As a result, shareholders' equity fell to $5,534.3 million from $7,149.8 million, working capital dropped to $179.2 million from $1,129.7 million, and $1,511.1 million of debt is current. Management plans to refinance this with long-term debt in 2008, so refinancing execution is a key near-term watch item. Cash and marketable securities declined to $2,115.8 million. Investors should weigh several risks. AVONEX and RITUXAN account for about 88% of revenue, TYSABRI carries PML safety risk and is limited to a restricted distribution program, and an activist proxy threat from Icahn Partners emerged in January 2008. Management also disclosed that a strategic review concluded in December 2007 with no definitive acquisition offers. Litigation exposure includes a securities class action on appeal, DOJ-related investigations involving Genentech, a qui tam False Claims Act case, and a Genentech arbitration over a change-of-control claim. The company also has about $300 million invested in the Hillerod, Denmark facility, with a potential impairment risk if TYSABRI demand does not materialize.
Feb 14, 2008
2006
BIOGEN INC. Annual Report, Year Ended Dec 31, 2006
Biogen Idec's 2006 Form 10-K shows a company in transition: total revenues rose 10.7% to $2.68 billion, net income reached $217.5 million ($0.63 diluted EPS) versus $160.7 million in 2005, and the company ended the year with $2.31 billion in cash and marketable securities. Growth is concentrated in two products: AVONEX (MS, $1.71 billion) and RITUXAN (co-promoted with Genentech, with Biogen's share of U.S. copromotion profits at $556 million plus $194 million in ex-U.S. royalties). Together these represent about 94% of revenues, so the company remains highly concentrated and exposed to competition in multiple sclerosis and to the Genentech relationship. The filing also highlights the relaunch of TYSABRI after its 2005 withdrawal over PML safety concerns. TYSABRI generated $35.8 million in 2006 sales, with U.S. and EU launches underway in the second half. The company is also pursuing a sizable pipeline and external growth. Acquisitions of Fumapharm and Conforma triggered $330.5 million in acquired IPR&D charges, which depressed reported profitability and drove a 56.6% effective tax rate. Management guided to higher 2007 R&D and SG&A spending, driven by the TYSABRI launch and business development. Key risks include ongoing litigation (TYSABRI securities class action, SEC investigation, DOJ probe of Genentech's RITUXAN promotion, False Claims Act suit, Medicaid pricing suits from multiple states), the RITUXAN change-of-control arbitration with Genentech, a Massachusetts tax assessment of $38.9 million, and the Hillerod, Denmark manufacturing investment, which totals roughly $500 million including the approved second phase. Balance-sheet strength and cash generation ($841 million operating cash flow) provide flexibility, but investors should weigh the single-product concentration and litigation exposure.
Feb 21, 2007
2005
BIOGEN INC. Annual Report, Year Ended Dec 31, 2005
Biogen Idec's 2005 10-K (filed March 3, 2006) shows a company in transition. Total 2005 revenues rose 10% to $2.42 billion from $2.21 billion, driven by AVONEX ($1.54 billion, up 9%) and RITUXAN copromotion and royalty income from Genentech and Roche. Net income improved sharply to $160.7 million ($0.47 diluted EPS) from $25.1 million in 2004, though this was still weighed down by $302 million of intangible amortization, a $118 million facility impairment and loss on the Oceanside NIMO plant sale, $66 million of purchase-accounting inventory costs for AMEVIVE, and $747.7 million of R&D spending. The filing's dominant risk is TYSABRI. Sales were suspended in February 2005 after progressive multifocal leukoencephalopathy (PML) cases, two of them fatal. An sBLA for MS was under FDA Priority Review with action expected around March 2006, and an advisory committee was scheduled for March 7, 2006. Management states that the outcome could range from permanent withdrawal to restricted-label reintroduction with a black box warning, and that the company could take inventory, intangible, or goodwill write-offs if it cannot return the drug. Several securities class actions, derivative suits, an SEC investigation, and product liability suits relate to the suspension. To address this, management launched a comprehensive strategic plan in September 2005 that cut about 17% of the workforce (roughly 650 positions), is divesting AMEVIVE and non-core Oceanside assets, and commits significant capital to external business development. Liquidity remains solid, with $2.1 billion in cash and marketable securities and $889.5 million of operating cash flow, though 2005 included $746.4 million to repurchase most of the 2002 senior notes and $322.6 million in buybacks. The RITUXAN rheumatoid arthritis indication was approved in February 2006, and the company's future growth depends heavily on TYSABRI's regulatory path and on AVONEX facing rising MS competition.
Mar 3, 2006
2004
BIOGEN INC. Annual Report, Year Ended Dec 31, 2004
Biogen Idec's 2004 10-K (filed March 31, 2005) reports total revenues of $2.21 billion, up from $679 million in 2003, but the year was defined by a sharp reversal in February 2005. Net income was only $25.1 million ($0.07 diluted EPS) and was dragged down by $289.5 million of purchase-accounting inventory step-up, $347.7 million of acquired-intangible amortization, and $686.7 million of R&D. Growth was driven by the November 2003 Merger with Biogen, Inc., which brought in AVONEX ($1.42 billion in 2004 sales) and a full year of the RITUXAN copromotion. AVONEX and RITUXAN together made up about 92% of revenue, so concentration risk is high. The central investor issue is TYSABRI. After its November 2004 FDA approval, the company and Elan voluntarily suspended marketing and dosing in February 2005 following two cases of progressive multifocal leukoencephalopathy (PML), and a March 30, 2005 review reassessed a Crohn's trial death as PML. Management cannot predict whether TYSABRI can be reintroduced. The filing discloses possible inventory and intangible write-offs, goodwill impairment risk, and facility impairments tied to the product. It also discloses multiple securities class actions, derivative suits, a demand letter, and an SEC informal inquiry related to insider stock sales. Balance-sheet and liquidity pressure is also significant. Senior convertible notes of about $753 million become puttable on April 29, 2005, and the company expects that a cash outflow of up to about $809 million will likely occur, which it plans to fund by liquidating marketable securities. Cash, equivalents and marketable securities fell to $2.2 billion. The company also repurchased about $734 million of stock in 2004, and its 2005 SG&A and R&D are expected to rise.
Mar 31, 2005
2003
BIOGEN INC. Annual Report, Year Ended Dec 31, 2003
Biogen Idec Inc. (formerly IDEC Pharmaceuticals) reported a 2003 net loss of $875.1 million, or $(4.92) per diluted share, versus net income of $148.1 million in 2002. The loss was driven by an $823 million non-cash write-off of acquired in-process R&D tied to the November 12, 2003 merger with Biogen, Inc., along with $173.9 million of inventory write-downs (largely AVONEX pre-filled syringe batches), a $79.1 million inventory step-up charge, and $33.2 million of intangible amortization. Total revenues rose to $679.2 million from $404.2 million, but only about two months of Biogen, Inc. results (November 13 to December 31, 2003) are included, so the reported figures understate the combined run-rate. Management says full-year 2004 product sales, royalties, SG&A and R&D will rise substantially. Revenue concentration remains high: AVONEX and RITUXAN together were about 94% of 2003 revenue, and Genentech copromotion profits on U.S. RITUXAN sales of $419.2 million made up 73% of total revenue. Cash, cash equivalents and marketable securities reached $2.3 billion, and shareholders' equity rose to $7.05 billion from $1.11 billion after the stock-based merger. Debt of about $887 million consists of zero-coupon convertible notes, with put dates in 2005 and 2007 that could require cash repayment. Key near-term catalysts include the planned mid-2004 BLA filing for ANTEGREN (natalizumab) in MS, the ZEVALIN settlement with Corixa (a $20 million payment), and manufacturing risk around AVONEX's pre-filled syringe. Ongoing litigation includes the Average Wholesale Price suits by New York counties and the Columbia University royalty dispute. Investors should weigh the strong cash position and growing portfolio against heavy revenue concentration, manufacturing quality issues, and the leverage that comes with the convertible debt.
Mar 10, 2004
2002-A
BIOGEN INC. Annual Report (Amendment), Year Ended Dec 31, 2002
This Form 10-K/A filing for IDEC Pharmaceuticals Corporation as of December 31, 2002, primarily serves to re-file a redacted Commercial Supply Agreement with Baxter Pharmaceutical Solutions LLC. While it does not introduce new financial information or material events post the original filing date, it provides an overview of the company's corporate structure and extensive list of agreements. Investors should note that this is an amended filing focused on a specific contractual document rather than a comprehensive update of the company's financial performance or strategic initiatives for the fiscal year 2002.
Oct 3, 2003
2002
BIOGEN INC. Annual Report, Year Ended Dec 31, 2002
This is IDEC Pharmaceuticals Corporation's (Nasdaq: IDPH) Form 10-K for fiscal 2002, filed March 31, 2003. The filing is IDEC's, not Biogen's, though the request named BIIB. IDEC later merged with Biogen in 2003 to form Biogen Idec. The company remains heavily dependent on Rituxan, a CD20 antibody it copromotes with Genentech in the U.S. Rituxan supplied about 95% of 2002 revenues. U.S. Rituxan net sales rose 39% to $1.08 billion, and IDEC's share of copromotion profits reached $324.5 million. Total revenues grew 48% to $404.2 million, and net income rose 46% to $148.1 million, or $0.85 diluted EPS, up from $0.59. Profitability improved and the balance sheet strengthened. The company released its entire deferred tax valuation allowance, which signals management's confidence in future taxable income. Operating income rose to $213.9 million. Year-end cash and securities totaled $1.45 billion after issuing $714 million of zero-coupon senior convertible notes due 2032, which carry a face value of $1.2 billion at maturity. The company also repurchased $135 million of stock. Total notes payable rose to $866 million from $136 million, and the company now carries meaningful convertible-debt leverage and put-option exposure in 2005 and 2007. Risks remain significant. Zevalin, the company's first self-marketed product, launched in April 2002 with only $13.7 million in sales, and its European launch is delayed. Zevalin faces patent litigation from Corixa and Glaxo, and a competing radioimmunotherapy, Bexxar, has an FDA goal date of May 2, 2003. Clinical development of IDEC-131 is on hold over a thromboembolism safety signal, and IDEC-114 was dropped for psoriasis. The company also depends on third parties for Zevalin's yttrium-90 supply and fill/finish, and it is building a roughly $400 million manufacturing facility in Oceanside, California.
Mar 31, 2003
2001
BIOGEN INC. Annual Report, Year Ended Dec 31, 2001
IDEC Pharmaceuticals Corporation, now known as Biogen Inc., reported strong revenue growth driven by its flagship product, Rituxan, which saw an 84% increase in U.S. net sales in 2001, reaching $779.0 million. This performance underscores Rituxan's significant market acceptance and its role as a leading therapy for B-cell non-Hodgkin's lymphomas (NHL). The company also achieved a major milestone with the FDA approval of its second product, ZEVALIN, in February 2002, positioning it as a complementary radioimmunotherapy for certain B-cell NHLs. IDEC's robust financial position, with $866.6 million in cash, cash equivalents, and securities available-for-sale as of December 31, 2001, supports its ongoing investment in a promising pipeline of autoimmune and inflammatory disease candidates, including IDEC-131, IDEC-114, IDEC-151, and IDEC-152, which are in various stages of clinical development. The company's strategic partnerships with Genentech, Roche, and Schering AG are crucial to its commercialization efforts for Rituxan and ZEVALIN, respectively. While Rituxan's manufacturing is handled by Genentech, IDEC is scaling up its own manufacturing capabilities for future products. Despite ongoing legal challenges concerning intellectual property, particularly related to Rituxan and ZEVALIN, IDEC Pharmaceuticals appears financially sound and well-positioned to navigate the competitive biopharmaceutical landscape.
Apr 1, 2002
2000
BIOGEN INC. Annual Report, Year Ended Dec 31, 2000
IDEC Pharmaceuticals Corporation, a biopharmaceutical company, is heavily reliant on its flagship product, Rituxan, for the majority of its revenue, which saw a significant 62% increase in 2000. The company is actively expanding its therapeutic pipeline, particularly in the treatment of B-cell non-Hodgkin's lymphomas (B-cell NHLs) and autoimmune diseases. A key strategic focus is the advancement of ZEVALIN, a promising radioimmunotherapy for B-cell NHLs, for which a BLA was accepted for filing by the FDA in December 2000. IDEC Pharmaceuticals is also developing a portfolio of antibody-based therapies for autoimmune and inflammatory conditions, leveraging its proprietary PRIMATIZED antibody technology. The company has established numerous strategic alliances with major pharmaceutical companies globally to support the development and commercialization of its products. Despite strong revenue growth driven by Rituxan, investors should note the significant concentration risk associated with this single product and the ongoing investments in research and development for its pipeline candidates.
Apr 2, 2001
1999
BIOGEN INC. Annual Report, Year Ended Dec 31, 1999
IDEC Pharmaceuticals Corporation, now Biogen Inc., reported 1999 total revenues of $118.0 million, up from $87.0 million in 1998, and net income of $43.2 million, or $0.86 per diluted share, compared with $21.5 million in 1998. Revenue growth was driven mainly by revenues from unconsolidated joint business, which rose to $93.2 million from $53.8 million, reflecting the commercialization of Rituxan through its copromotion arrangement with Genentech. Rituxan U.S. net sales by Genentech were $262.7 million in 1999, a 73% increase over $152.1 million in 1998. The company's income from operations was $41.4 million, and it ended 1999 with $246.3 million in cash, cash equivalents and securities available-for-sale, up from $73.5 million a year earlier, after raising about $112.7 million net from zero coupon convertible notes in February 1999. The company's revenue remains heavily concentrated in a single product. The filing states that approximately 79% of 1999 total revenues were derived from its collaboration and joint business arrangement with Genentech. The company transferred all bulk Rituxan manufacturing to Genentech in September 1999, which the filing says will reduce manufacturing revenue and costs going forward. Its lead pipeline product, ZEVALIN, completed patient accrual in two pivotal Phase III studies, and a Biologics License Application is expected to be submitted in the fourth quarter of 2000, subject to FDA approval. Other candidates include IDEC-114 in psoriasis, IDEC-131 in SLE, and IDEC-152 in allergic asthma, all in clinical development. The filing also highlights risk factors investors should weigh. These include dependence on Rituxan sales, uncertain clinical trial outcomes, reliance on third-party manufacturers and suppliers, and a patent interference proceeding relating to anti-CD40L antibodies. The company stated it was not a party to any material legal proceedings. Its 2019 zero coupon notes carry a $345.0 million face value, and holders may require repurchase on February 16, 2004, 2009 or 2014.
Mar 30, 2000
1995-A
BIOGEN INC. Annual Report (Amendment), Year Ended Dec 31, 1995
This filing is a Form 10-K/A from Biogen, Inc. (BIIB), dated June 6, 1996, covering fiscal year 1995. The excerpt contains only the cover page and Part IV (Exhibits and Reports on Form 8-K). It does not include the financial statements, MD&A, or business discussion. Those are incorporated by reference from the 1995 Annual Report to Shareholders (Exhibit 13.0), which is not part of this excerpt, so revenue, net income, R&D spending, and cash position cannot be assessed from it. The cover page reports about 15,099,229 common shares outstanding as of January 31, 1996, and an aggregate market value held by non-affiliates of approximately $303.6 million, based on the Nasdaq National Market closing price on that date. The stated 1996 annual meeting date was May 22, 1996. No Form 8-K reports were filed in the fourth quarter of 1995. The exhibit list shows a heavy reliance on collaborations and licensing. Several agreements were entered into in late 1995 with Eisai, Zenyaku Kogyo, and Genentech, and there are continuing arrangements with SmithKline Beecham, Seikagaku, and Mitsubishi Chemical. Many of these agreements carry confidential treatment requests, so their economic terms are not disclosed in this filing. Investors would need the full annual report and the underlying agreements to evaluate the company's financial position and partnership economics.
Jun 6, 1996